TY - JOUR

T1 - Term amniotic fluid: an unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications.

AU - Moraghebi, Roksana

AU - Kirkeby, Agnete

AU - Chaves, Patricia

AU - Roenn, Roger E.

AU - Sitnicka, Ewa

AU - Parmar, Malin

AU - Larsson, Marcus

AU - Herbst, Andreas

AU - Woods, Niels-Bjarne.

N1 - M1 - Copyright (C) 2018 American Chemical Society (ACS). All Rights Reserved. CAPLUS AN 2018:565685(Journal; Online Computer File)

PY - 2017/8/25

Y1 - 2017/8/25

N2 - Background: Mesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clin. and clin. cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modeling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low vols. of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming. Methods: Amniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages. Results: The av. vol. of term amniotic fluid collected was approx. 0.4 L per donor, contg. an av. of 7 million viable mononuclear cells per L, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential. Conclusions: The potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modeling, and regenerative medicine applications. [on SciFinder(R)]

AB - Background: Mesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clin. and clin. cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modeling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low vols. of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming. Methods: Amniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages. Results: The av. vol. of term amniotic fluid collected was approx. 0.4 L per donor, contg. an av. of 7 million viable mononuclear cells per L, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential. Conclusions: The potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modeling, and regenerative medicine applications. [on SciFinder(R)]

U2 - 10.1186/s13287-017-0582-6

DO - 10.1186/s13287-017-0582-6

M3 - Journal article

C2 - 28841906

VL - 8

JO - Stem Cell Research & Therapy

JF - Stem Cell Research & Therapy

SN - 1757-6512

M1 - 190

ER -